Palliative exenteration--what, when, and why?
Between 1955 and 1981, 323 pelvic exenterations were performed at the Mayo Clinic. Fifty-nine (18%) were considered retrospectively to be palliative because of pelvic or aortic nodal metastasis, pelvic peritoneal involvement, pelvic wall involvement, bone involvement, or, in two cases, distant metastasis. The survivals were 47% at 2 years and 17% at 5 years. When metastatic nodal disease was found after irradiated pelvic recurrence, the 2- and 5-year survivals were 46% and 23%, respectively. Although exenteration procedures are designed to be curative, the palliative benefits obtained in this group of patients appear to be worthwhile and comparable to those achieved in advanced epithelial ovarian carcinoma for which aggressive surgical management is now strongly advocated.
Stanhope
C R
CR
Symmonds
R E
RE
D001859:Bone Neoplasms / Q000556:secondary; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D010166:Palliative Care; D010385:Pelvic Exenteration / Q000401:mortality*; D010386:Pelvic Neoplasms / Q000556:secondary / Q000601:surgery*; D010534:Peritoneal Neoplasms / Q000556:secondary; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy / Q000601:surgery